Local view for "http://purl.org/linkedpolitics/eu/plenary/2013-02-06-Speech-3-203-750"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2013-02-06"^^xsd:date2
dcterms:Is Part Of	lp_eu:Transparency of measures regulating the prices of medicinal products for human use (A7-0015/2013 - Antonyia Parvanova)2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20130206.25.3-203-750"2
lpv:hasSubsequent	lp_eu:2013-02-06-Speech-3-204-5002
lpv:speaker	lp:Jill Evans2
lpv:spoken text	"I abstained in the vote on this report. The current directive on the pricing of medicines reflects the market conditions of twenty years ago. However, these conditions have changed with the rise of generic medicines on the one hand and of expensive innovative medicines on the other hand. Generic products are on average 40% cheaper than the branded medicines once they have been available for two years. Although the report recognises these problems, it does not go far enough and in abstaining I wanted to flag these problems. It is important that we address the situation correctly. In Wales prescriptions are free to patients but speeding up the availability of generic medicines could save substantial sums for the NHS."@en1
lpv:spokenAs	substitute; Delegation for relations with the Palestinian Legislative Council (2009-09-16--2014-06-30)3 unknown; Plaid Cymru - Party of Wales (2009-07-14--2014-06-30)3 substitute; AGRI (2012-01-19--2014-06-30)3 vice-chair; G/EFA (2009-07-14--2014-06-30)3 substitute; Delegation for relations with Iraq (2011-02-14--2014-06-30)3 member; ENVI (2012-01-19--2014-06-30)3
lpv:unclassifiedMetadata	"Jill Evans (Verts/ALE ),"1 "in writing"1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph